YFJ-36 is an antibiotic that demonstrates superior and broad-spectrum antibacterial activity in vitro compared to cefiderocol, particularly against A. baumannii and K. pneumoniae. In a systemic infection model in mice, YFJ-36 exhibits strong in vivo efficacy. Additionally, the compound shows enhanced physicochemical stability in liquid media with a pH of 6-8 and is noteworthy for its potential to reduce allergy risk due to its quaternary ammonium bond.